Research
Hormonal
Disruption of circadian rhythms (e.g., via shift work or jet lag) impairs health by desynchronizing peripheral tissue clocks from the central SCN pacemaker, leading to metabolic and endocrine dysfunction.
Your body has an internal master clock (SCN) and local clocks in organs like the liver. These must be synchronized. Shift work, late-night eating, or irregular sleep desynchronizes them, increasing disease risk. Align your sleep, light exposure, and meal times with your local day/night cycle to maintain metabolic health.
GoodSupportsHIGH confidence
disturbances to circadian timing arising from modern working schedules are becoming recognized as an increasingly relevant factor in the newly identified major molecular components of circadian control systems provide novel avenues for therapeutic intervention.
Why this rating
High-quality review of molecular genetics and physiology in mammals, citing multiple mutant models and human studies.
Source
Circadian clocks: regulators of endocrine and metabolic rhythms
Michael H. Hastings et al. · Journal of Endocrinology · 2007
DOI 10.1677/joe-07-0378
narrative_reviewCited 422×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Glucocorticoids (corticosteroids) act as a primary synchronizing signal from the central SCN to peripheral clocks, particularly in the liver, regulating up to 60% of the hepatic transcriptome.Strong
- Light exposure at specific times (dusk/dawn) resets the central SCN clock by inducing Per1/Per2 gene expression, with the direction of the shift (advance vs. delay) depending on the timing of light exposure.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →